TLDR Early treatment of Folliculitis Decalvans in children can improve inflammation and partially regrow hair.
This case series investigates three pediatric cases of Folliculitis Decalvans (FD), a rare inflammatory scalp disorder causing cicatricial alopecia. The study focuses on the clinical, trichoscopic, and histopathological characteristics of FD in children, a group with limited data on this condition. All cases involved methicillin-resistant Staphylococcus aureus infections and were treated with antibiotics, dapsone, and cetrimide shampoo, leading to significant improvement and partial hair regrowth after 16 weeks. The study highlights the rarity and severity of FD in children, stressing the importance of early intervention to prevent permanent hair loss and psychological distress. Despite the small sample size, the findings offer valuable insights into managing pediatric FD.
40 citations
,
August 2018 in “Journal of the American Academy of Dermatology” Clindamycin and rifampicin are the most effective treatments for folliculitis decalvans, but more research is needed.
41 citations
,
June 2018 in “Journal of The American Academy of Dermatology” Some treatments for folliculitis decalvans work well, with tetracyclines and a mix of rifampicin and clindamycin being most effective.
39 citations
,
July 2000 in “British Journal of Dermatology” Identical twins both had a rare hair loss condition, suggesting it might be genetic.
May 2025 in “JAAD reviews.” Current treatments for neutrophilic alopecias in children are limited and often ineffective, especially for males and those of Afro-Caribbean descent.
1 citations
,
January 2022 in “Skin appendage disorders” DCPA is a chronic skin condition affecting the legs, often misdiagnosed, and needs more research for better understanding and treatment.
November 2019 in “Harper's Textbook of Pediatric Dermatology” The document is a detailed medical reference on skin and genetic disorders.
7 citations
,
January 2023 in “Anti-Cancer Drugs” Early diagnosis and treatment of EGFR inhibitor-induced folliculitis decalvans can prevent permanent hair loss.
January 2025 in “Annals of Dermatology” PCA patients have more harmful bacteria and antibiotic resistance, needing specific testing for treatment.